文献速递心脑血管急症消化、代谢与肾脏急症

现实使用中非甾体抗炎药与急性心肌梗死风险:个体患者数据的贝叶斯Meta分析

Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.
PubMed 文献 · BMJ · 2017-05-09
一句话结论所有非甾体抗炎药(包括萘普生)使用后急性心肌梗死风险均升高,风险在使用第一个月内和较高剂量时最大,塞来昔布风险与传统NSAIDs相当且低于罗非昔布。

该研究为系统综述及单阶段贝叶斯个体患者数据Meta分析,数据来自加拿大和欧洲医疗数据库,纳入446763例个体(其中61460例发生急性心肌梗死)。分析显示,使用任何剂量非甾体抗炎药1周、1个月或超过1个月均与心肌梗死风险升高相关;使用1至7天时,塞来昔布、布洛芬、双氯芬酸、萘普生和罗非昔布的风险升高后验概率分别为92%、97%、99%、99%和99%,对应比值比(95%可信区间)分别为1.24(0.91至1.82)、1.48(1.00至2.26)、1.50(1.06至2.04)、1.53(1.07至2.33)和1.58(1.07至2.17)。较高剂量非甾体抗炎药的心肌梗死风险更高;使用超过1个月的风险似乎未超过较短疗程。结论认为所有非甾体抗炎药均与急性心肌梗死风险升高相关,塞来昔布风险与传统NSAIDs相当且低于罗非昔布,风险在用药第一个月内和较高剂量时最大。

要点

  • 使用任何剂量非甾体抗炎药1周、1个月或超过1个月均与急性心肌梗死风险升高相关。
  • 使用1至7天时,心肌梗死风险升高的后验概率:塞来昔布92%、布洛芬97%、双氯芬酸99%、萘普生99%、罗非昔布99%。
  • 对应比值比(95%可信区间):塞来昔布1.24(0.91至1.82)、布洛芬1.48(1.00至2.26)、双氯芬酸1.50(1.06至2.04)、萘普生1.53(1.07至2.33)、罗非昔布1.58(1.07至2.17)。
  • 较高剂量非甾体抗炎药的心肌梗死风险更高;使用超过1个月的风险似乎未超过较短疗程。
  • 塞来昔布的心肌梗死风险与传统NSAIDs相当,且低于罗非昔布。

适用人群与场景

  • 来自加拿大和欧洲医疗数据库的一般人群或老年人群,纳入446763例个体,其中61460例发生急性心肌梗死。

研究设计与关键结果

  • 系统综述及单阶段贝叶斯个体患者数据Meta分析,数据来自加拿大和欧洲医疗数据库,纳入446763例个体(其中61460例急性心肌梗死)。
  • 使用任何剂量非甾体抗炎药1周、1个月或超过1个月均与心肌梗死风险升高相关。
  • 使用1至7天时,心肌梗死风险升高的后验概率(比值比>1.0):塞来昔布92%、布洛芬97%、双氯芬酸99%、萘普生99%、罗非昔布99%。
  • 使用1至7天时比值比(95%可信区间):塞来昔布1.24(0.91至1.82)、布洛芬1.48(1.00至2.26)、双氯芬酸1.50(1.06至2.04)、萘普生1.53(1.07至2.33)、罗非昔布1.58(1.07至2.17)。
  • 较高剂量非甾体抗炎药的心肌梗死风险更高;使用超过1个月的风险似乎未超过较短疗程。

证据类型、等级与局限

  • 证据类型:系统综述及单阶段贝叶斯个体患者数据Meta分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于有急性心肌梗死风险的患者,处方任何非甾体抗炎药(包括萘普生)时需考虑用药第一个月内和较高剂量时风险最大。
  • 塞来昔布的心肌梗死风险与传统NSAIDs相当且低于罗非昔布,但所有非甾体抗炎药均与风险升高相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Objective To characterise the determinants, time course, and risks of acute myocardial infarction associated with use of oral non-steroidal anti-inflammatory drugs (NSAIDs).Design Systematic review followed by a one stage bayesian individual patient data meta-analysis.Data sources Studies from Canadian and European healthcare databases.Review methods Eligible studies were sourced from computerised drug prescription or medical databases, conducted in the general or an elderly population, documented acute myocardial infarction as specific outcome, studied selective cyclo-oxygenase-2 inhibitors (including rofecoxib) and traditional NSAIDs, compared risk of acute myocardial infarction in NSAID users with non-users, allowed for time dependent analyses, and minimised effects of confounding and misclassification bias. Exposure and outcomes Drug exposure was modelled as an indicator variable incorporating the specific NSAID, its recency, duration of use, and dose. The outcome measures were the summary adjusted odds ratios of first acute myocardial infarction after study entry for each category of NSAID use at index date (date of acute myocardial infarction for cases, matched date for controls) versus non-use in the preceding year and the posterior probability of acute myocardial infarction.Results A cohort of 446 763 individuals including 61 460 with acute myocardial infarction was acquired. Taking any dose of NSAIDs for one week, one month, or more than a month was associated with an increased risk of myocardial infarction. With use for one to seven days the probability of increased myocardial infarction risk (posterior probability of odds ratio >1.0) was 92% for celecoxib, 97% for ibuprofen, and 99% for diclofenac, naproxen, and rofecoxib. The corresponding odds ratios (95% credible intervals) were 1.24 (0.91 to 1.82) for celecoxib, 1.48 (1.00 to 2.26) for ibuprofen, 1.50 (1.06 to 2.04) for diclofenac, 1.53 (1.07 to 2.33) for naproxen, and 1.58 (1.07 to 2.17) for rofecoxib. Greater risk of myocardial infarction was documented for higher dose of NSAIDs. With use for longer than one month, risks did not appear to exceed those associated with shorter durations.Conclusions All NSAIDs, including naproxen, were found to be associated with an increased risk of acute myocardial infarction. Risk of myocardial infarction with celecoxib was comparable to that of traditional NSAIDS and was lower than for rofecoxib. Risk was greatest during the first month of NSAID use and with higher doses.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017. PMID: 28487435. doi:10.1136/bmj.j1909

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。